Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2015-2017

ABSTRACT

The potential role of ATIII in achieving and maintaining adequate anticoagulation in pediatric patients on the heart-lung machine has recently taken on increased importance as caregivers strive to mitigate the risk for clinically significant clotting problems. It is known that ATIII levels are decreased in normal neonates and infants less than 6 months of age relative to older children and adults and become even further decreased in critically ill neonates and infants, including those with congenital heart disease. The current utilization of ATIII in the context of support on a heart-lung machine is based on pharmacokinetic data derived from adult subjects with congenital ATIII deficiency. There is a gap in knowledge as to the appropriate frequency of ATIII repletion, best method of monitoring, and mode of administration in critically ill neonates and infants receiving support on a heart-lung machine.Our long-term goal is to determine if antithrombin (ATIII) can effectively change the coagulation system in patients undergoing heart-lung machine support. The objective of this proposal, which is our first step in pursuit of that goal, is to determine the pharmacokinetics of ATIII in neonates and infants. Our central hypothesis is that ATIII will have different pharmacokinetic properties in neonates and infants than adults and these properties will be affected by the use of heart-lung machine. This research will result in critical data on the pharmacokinetics of ATIII in neonates and infants receiving heart-lung machine support. This contribution is significant because it is the first step in a continuum of research that is expected to lead to the development of a therapeutic strategy employing ATIII that will facilitate improved modulation of the coagulation cascade to prevent significant clotting and bleeding complications in pediatric patients requiring heart-lung machine support. Detailed Description This is a single-site, prospective, open-label, pharmacokinetic study of hpATIII in neonates and infants. Patients admitted to the Cardiac Intensive Care Unit (CICU) and the Neonatal Intensive Care Unit (NICU) at Cincinnati Children's Hospital Medical Center (CCHMC) will be enrolled. Participants will be enrolled into one of three cohorts depending on whether they are scheduled for ECMO, CPB, or neither, and based on age (neonate or infant). Two doses of hpATIII will be used; one according to current labelling for hpATIII and one that accounts for the additional circuit volume from ECMO or CPB. Pharmacokinetic measurements will be obtained for all groups at baseline prior to administration of hpATIII and at multiple defined times up to 120 hrs following each administration of hpATIII. Administration of hpATIII is standard of care at CCHMC for participants undergoing ECMO. The standard dose administered for clinical care is (120 - baseline AT activity level) x weight (kg) / 1.4. For participants not undergoing ECMO for clinical care, or for those undergoing ECMO but receiving an adjusted dose for additional circuit volume , the administration of hpATIII is considered research. The duration of the study at CCHMC is expected to be 2.5 years. This includes 24 months for recruitment and data collection, and 6 months for data analysis and report writing. Individual participants will be in the study for approximately 120 hours (5 days) following administration of hpATIII. If participants receive more than 1 dose, they will be in the study for approximately 120 hours following each dose of hpATIII received. More... »

URL

https://clinicaltrials.gov/show/NCT02631174

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The potential role of ATIII in achieving and maintaining adequate anticoagulation in pediatric patients on the heart-lung machine has recently taken on increased importance as caregivers strive to mitigate the risk for clinically significant clotting problems. It is known that ATIII levels are decreased in normal neonates and infants less than 6 months of age relative to older children and adults and become even further decreased in critically ill neonates and infants, including those with congenital heart disease. The current utilization of ATIII in the context of support on a heart-lung machine is based on pharmacokinetic data derived from adult subjects with congenital ATIII deficiency. There is a gap in knowledge as to the appropriate frequency of ATIII repletion, best method of monitoring, and mode of administration in critically ill neonates and infants receiving support on a heart-lung machine.Our long-term goal is to determine if antithrombin (ATIII) can effectively change the coagulation system in patients undergoing heart-lung machine support. The objective of this proposal, which is our first step in pursuit of that goal, is to determine the pharmacokinetics of ATIII in neonates and infants. Our central hypothesis is that ATIII will have different pharmacokinetic properties in neonates and infants than adults and these properties will be affected by the use of heart-lung machine. This research will result in critical data on the pharmacokinetics of ATIII in neonates and infants receiving heart-lung machine support. This contribution is significant because it is the first step in a continuum of research that is expected to lead to the development of a therapeutic strategy employing ATIII that will facilitate improved modulation of the coagulation cascade to prevent significant clotting and bleeding complications in pediatric patients requiring heart-lung machine support.\n\nDetailed Description\nThis is a single-site, prospective, open-label, pharmacokinetic study of hpATIII in neonates and infants. Patients admitted to the Cardiac Intensive Care Unit (CICU) and the Neonatal Intensive Care Unit (NICU) at Cincinnati Children's Hospital Medical Center (CCHMC) will be enrolled. Participants will be enrolled into one of three cohorts depending on whether they are scheduled for ECMO, CPB, or neither, and based on age (neonate or infant). Two doses of hpATIII will be used; one according to current labelling for hpATIII and one that accounts for the additional circuit volume from ECMO or CPB. Pharmacokinetic measurements will be obtained for all groups at baseline prior to administration of hpATIII and at multiple defined times up to 120 hrs following each administration of hpATIII. Administration of hpATIII is standard of care at CCHMC for participants undergoing ECMO. The standard dose administered for clinical care is (120 - baseline AT activity level) x weight (kg) / 1.4. For participants not undergoing ECMO for clinical care, or for those undergoing ECMO but receiving an adjusted dose for additional circuit volume , the administration of hpATIII is considered research. The duration of the study at CCHMC is expected to be 2.5 years. This includes 24 months for recruitment and data collection, and 6 months for data analysis and report writing. Individual participants will be in the study for approximately 120 hours (5 days) following administration of hpATIII. If participants receive more than 1 dose, they will be in the study for approximately 120 hours following each dose of hpATIII received.", 
    "endDate": "2017-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02631174", 
    "keywords": [
      "pharmacokinetics", 
      "antithrombin III", 
      "infant", 
      "potential role", 
      "achieving", 
      "anticoagulation", 
      "pediatric patient", 
      "heart-lung machine", 
      "increased importance", 
      "caregiver", 
      "risk", 
      "clotting", 
      "age", 
      "old child", 
      "adult", 
      "Newborn Infant", 
      "congenital heart disease", 
      "utilization", 
      "pharmacokinetic data", 
      "adult subject", 
      "deficiency", 
      "gap", 
      "frequency", 
      "repletion", 
      "method", 
      "mode", 
      "Organization and Administration", 
      "long-term goal", 
      "coagulation system", 
      "patient", 
      "first step", 
      "pursuit", 
      "central hypothesis", 
      "pharmacokinetic property", 
      "critical data", 
      "contribution", 
      "continuum", 
      "development", 
      "therapeutic strategy", 
      "modulation", 
      "coagulation cascade", 
      "bleeding complication", 
      "single site", 
      "pharmacokinetic study", 
      "intensive care unit", 
      "neonatal intensive care unit", 
      "Cincinnati Children's Hospital Medical Center", 
      "cohort", 
      "extracorporeal membrane oxygenation", 
      "CPB", 
      "dose", 
      "labeling", 
      "circuit", 
      "baseline", 
      "defined time", 
      "hr", 
      "care", 
      "standard dose", 
      "clinical care", 
      "activity level", 
      "weight", 
      "Research", 
      "duration", 
      "recruitment", 
      "Data Collection", 
      "Statistic as Topic", 
      "individual participant"
    ], 
    "name": "Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02631174"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00020.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.476368.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.239573.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2015-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1016/j.jtcvs.2004.10.045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011565141"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2005.05753.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022280498"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1213/01.ane.0000297290.03501.db", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037319920"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01070904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041304116", 
          "https://doi.org/10.1007/bf01070904"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02631174"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02631174'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02631174'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02631174'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02631174'


 

This table displays all metadata directly associated to this object as RDF triples.

101 TRIPLES      16 PREDICATES      87 URIs      76 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02631174 schema:about anzsrc-for:3048
2 schema:description The potential role of ATIII in achieving and maintaining adequate anticoagulation in pediatric patients on the heart-lung machine has recently taken on increased importance as caregivers strive to mitigate the risk for clinically significant clotting problems. It is known that ATIII levels are decreased in normal neonates and infants less than 6 months of age relative to older children and adults and become even further decreased in critically ill neonates and infants, including those with congenital heart disease. The current utilization of ATIII in the context of support on a heart-lung machine is based on pharmacokinetic data derived from adult subjects with congenital ATIII deficiency. There is a gap in knowledge as to the appropriate frequency of ATIII repletion, best method of monitoring, and mode of administration in critically ill neonates and infants receiving support on a heart-lung machine.Our long-term goal is to determine if antithrombin (ATIII) can effectively change the coagulation system in patients undergoing heart-lung machine support. The objective of this proposal, which is our first step in pursuit of that goal, is to determine the pharmacokinetics of ATIII in neonates and infants. Our central hypothesis is that ATIII will have different pharmacokinetic properties in neonates and infants than adults and these properties will be affected by the use of heart-lung machine. This research will result in critical data on the pharmacokinetics of ATIII in neonates and infants receiving heart-lung machine support. This contribution is significant because it is the first step in a continuum of research that is expected to lead to the development of a therapeutic strategy employing ATIII that will facilitate improved modulation of the coagulation cascade to prevent significant clotting and bleeding complications in pediatric patients requiring heart-lung machine support. Detailed Description This is a single-site, prospective, open-label, pharmacokinetic study of hpATIII in neonates and infants. Patients admitted to the Cardiac Intensive Care Unit (CICU) and the Neonatal Intensive Care Unit (NICU) at Cincinnati Children's Hospital Medical Center (CCHMC) will be enrolled. Participants will be enrolled into one of three cohorts depending on whether they are scheduled for ECMO, CPB, or neither, and based on age (neonate or infant). Two doses of hpATIII will be used; one according to current labelling for hpATIII and one that accounts for the additional circuit volume from ECMO or CPB. Pharmacokinetic measurements will be obtained for all groups at baseline prior to administration of hpATIII and at multiple defined times up to 120 hrs following each administration of hpATIII. Administration of hpATIII is standard of care at CCHMC for participants undergoing ECMO. The standard dose administered for clinical care is (120 - baseline AT activity level) x weight (kg) / 1.4. For participants not undergoing ECMO for clinical care, or for those undergoing ECMO but receiving an adjusted dose for additional circuit volume , the administration of hpATIII is considered research. The duration of the study at CCHMC is expected to be 2.5 years. This includes 24 months for recruitment and data collection, and 6 months for data analysis and report writing. Individual participants will be in the study for approximately 120 hours (5 days) following administration of hpATIII. If participants receive more than 1 dose, they will be in the study for approximately 120 hours following each dose of hpATIII received.
3 schema:endDate 2017-06-01T00:00:00Z
4 schema:keywords CPB
5 Cincinnati Children's Hospital Medical Center
6 Data Collection
7 Newborn Infant
8 Organization and Administration
9 Research
10 Statistic as Topic
11 achieving
12 activity level
13 adult
14 adult subject
15 age
16 anticoagulation
17 antithrombin III
18 baseline
19 bleeding complication
20 care
21 caregiver
22 central hypothesis
23 circuit
24 clinical care
25 clotting
26 coagulation cascade
27 coagulation system
28 cohort
29 congenital heart disease
30 continuum
31 contribution
32 critical data
33 deficiency
34 defined time
35 development
36 dose
37 duration
38 extracorporeal membrane oxygenation
39 first step
40 frequency
41 gap
42 heart-lung machine
43 hr
44 increased importance
45 individual participant
46 infant
47 intensive care unit
48 labeling
49 long-term goal
50 method
51 mode
52 modulation
53 neonatal intensive care unit
54 old child
55 patient
56 pediatric patient
57 pharmacokinetic data
58 pharmacokinetic property
59 pharmacokinetic study
60 pharmacokinetics
61 potential role
62 pursuit
63 recruitment
64 repletion
65 risk
66 single site
67 standard dose
68 therapeutic strategy
69 utilization
70 weight
71 schema:name Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support
72 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02631174
73 schema:sdDatePublished 2019-03-07T15:26
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N899c068635d54f70a88b008e2bca462f
76 schema:sponsor https://www.grid.ac/institutes/grid.239573.9
77 https://www.grid.ac/institutes/grid.476368.8
78 schema:startDate 2015-06-01T00:00:00Z
79 schema:subjectOf sg:pub.10.1007/bf01070904
80 https://doi.org/10.1016/j.jtcvs.2004.10.045
81 https://doi.org/10.1111/j.1365-2141.2005.05753.x
82 https://doi.org/10.1213/01.ane.0000297290.03501.db
83 schema:url https://clinicaltrials.gov/show/NCT02631174
84 sgo:license sg:explorer/license/
85 sgo:sdDataset clinical_trials
86 rdf:type schema:MedicalStudy
87 N899c068635d54f70a88b008e2bca462f schema:name Springer Nature - SN SciGraph project
88 rdf:type schema:Organization
89 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
90 rdf:type schema:DefinedTerm
91 sg:pub.10.1007/bf01070904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041304116
92 https://doi.org/10.1007/bf01070904
93 rdf:type schema:CreativeWork
94 https://doi.org/10.1016/j.jtcvs.2004.10.045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011565141
95 rdf:type schema:CreativeWork
96 https://doi.org/10.1111/j.1365-2141.2005.05753.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022280498
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1213/01.ane.0000297290.03501.db schema:sameAs https://app.dimensions.ai/details/publication/pub.1037319920
99 rdf:type schema:CreativeWork
100 https://www.grid.ac/institutes/grid.239573.9 schema:Organization
101 https://www.grid.ac/institutes/grid.476368.8 schema:Organization
 




Preview window. Press ESC to close (or click here)


...